PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-16.72%
Cash & equivalents declining -16.72% while AGEN's grows 48.96%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Below half of AGEN's 62.00%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AGEN's -24.28%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-19.08%
Below half of AGEN's 51.08%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-14.24%
≥ 1.5x AGEN's -0.68%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.11%
≥ 1.5x AGEN's -0.54%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Below half of AGEN's 29.48%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-4.20%
Less than half of AGEN's -11.25%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.87%
Exceeding 1.5x AGEN's 25.31%. Michael Burry suspects ballooning short-term obligations vs. competitor.
18.79%
Less than half of AGEN's -11.01%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.79%
Less than half of AGEN's -0.89%. David Dodd sees far fewer liability expansions relative to competitor.
2.42%
Less than half of AGEN's 12.42%. David Dodd sees fewer share issuances vs. competitor.
-5.90%
≥ 1.5x AGEN's -2.02%. David Dodd sees higher yoy retained profits than competitor.
-12.27%
1.25-1.5x AGEN's -8.62%. Martin Whitman is wary of bigger swings in AOCI.
No Data
No Data available this quarter, please select a different quarter.
-28.51%
Below half AGEN's 122.76%. Michael Burry sees potential underperformance in building shareholder capital.
-19.02%
Below half AGEN's 29.48%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.72%
Less than half of AGEN's -62.33%. David Dodd sees better deleveraging or stronger cash buildup than competitor.